Oncologic Effects of Primary Tumor-Sidedness on Patients with Stages 1–3 Colon Cancer: A Meta-Analysis
- 88 Downloads
Previous studies comparing the oncologic outcomes of primary tumor-sidedness for patients with colon cancer have reported a worse prognosis for those with right-sided tumors. However, most of these studies evaluated patients with metastatic disease.
PubMed, EMBASE, and the Cochrane Library were searched for studies that assessed the effects of primary tumor-sidedness on survival outcomes for patients with stages 1, 2, and 3 colon cancer. The hazard ratio (HR) for primary tumor location was estimated for overall survival (OS), cancer-specific survival (CSS) and disease-free survival (DFS).
The inclusion criteria were met by 37 studies involving 581,542 patients. The patients with a right-sided tumor had better CSS (HR, 0.67; 95% confidence interval [CI], 0.56–0.80; p < 0.0001) among those with stage 1 cancer as well as better OS (HR, 0.89; 95% CI 0.86–0.92; I2 = 19%) and CSS (HR, 0.78; 95% CI 0.70–0.86; I2 = 78%) among those with stage 2 cancer. In contrast, among the patients with stage 3 cancer, those with a right-sided tumor had worse OS (HR, 1.12; 95% CI 1.04–1.20; p = 0.002), CSS (HR, 1.05; 95% CI 1.01–1.10; p = 0.02), and DFS (HR, 1.32; 95% CI 1.07–1.63; p = 0.008).
Primary tumor location may be a prognostic factor for patients with non-metastatic colon cancer. The prognosis for patients with right-sided tumor may be better for those with stage 1 or 2 cancer, but worse for those with stage 3 cancer.
There are no conflicts of interest.
- 7.Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0, vol. 5. Wiley, Chichester, United Kingdom, 2011.Google Scholar
- 8.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Retrieved 1 Oct 2017 at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 18.Liu F, Li C, Jia H, et al. Is there a prognostic value of tumor location among Chinese patients with colorectal cancer? Oncotarget. 2017;8:38682–92.Google Scholar
- 26.Pectasides D, Karavasilis V, Papaxoinis G, et al. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) as adjuvant therapy inpatients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer. 2015;15:384.CrossRefGoogle Scholar
- 36.Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53:57–64.CrossRefGoogle Scholar
- 48.Jeong DH, Kim WR, Min BS, Kim YW, Song MK, Kim NK. Validation of a quantitative 12-multigene expression assay (Oncotype DX(®) Colon Cancer Assay) in Korean patients with stage II colon cancer: implication of ethnic differences contributing to differences in gene expression. Onco Targets Ther. 2015;8:3817–25.Google Scholar
- 56.Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, Slattery ML. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001;10:917–23.Google Scholar